Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Addis Ababa University | OTHER |
| Armauer Hansen Research Institute, Ethiopia | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim with study is to provide adjunctive therapy with vitamin D and phenylbutyrate together with standard anti-tuberculosis treatment to significantly improve clinical recovery among patients with untreated, active pulmonary tuberculosis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate) | Active Comparator | Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks. |
|
| Placebo tablets | Placebo Comparator | Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate) | Drug | Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Composite clinical TB score | A previously described composite clinical TB score will be used to monitor the efficacy of vitamin D and phenylbutyrate treatment among TB patients on standard chemotherapy. The numerical TB score will include self-reported clinical symptoms (cough, night sweats and chest pain) as well as different parameters determined upon clinical examination anemia, haemoptysis, dyspnoea, tachycardia, positive finding at lung auscultation, fever, low body mass index (BMI) and low mid upper arm circumference (MUAC). The TB score will be determined at the time of diagnosis (time point 0) and at 4, 8, 16 and 24 weeks after initiation of antimicrobial treatment with vitamin D and phenylbutyrate. The primary endpoint will be assessed at time point 8 weeks compared to baseline (time point 0). | 0 (baseline) compared to 8 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical secondary endpoints | Clinical composite TB score (0, 4, 16, 24 weeks). Modified clinical composite TB score (0, 4, 8, 16, 24 weeks). Chest X-ray (0, 4, 8, 16, 24 weeks). Time to sputum- and/or TB culture conversion (0, 1, 2, 3, 4, 8 weeks). | 0-4, 8, 16 and 24 weeks |
| Laboratory secondary endpoints |
Not provided
Inclusion Criteria:
HIV negative patients, adult patients >18 years who has not started anti-TB therapy.
Newly diagnosed pulmonary TB confirmed by microscopy or culture but also sputum-negative clinical TB cases (defined according to the WHO 2006 criteria for sputum smear-negative TB ie. clinical symptoms of TB, chest X-ray findings and response to standard treatment).
Exclusion Criteria:
Patients who have already started treatment with anti-TB drugs for more that 5 days.
HIV-positive patients.
History of anti-TB treatment in the past 2 years.
Local extra-pulmonary TB in the absence of lung manifestations.
Hypercalcaemia (serum calcium > 3 mmol/L) identified at baseline.
Pregnant and breast feeding women.
Any known liver or kidney function abnormality, malignancy or patients treated with cardiac glycosides.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Susanna Brighenti, PhD | Karolinska Institutet | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine | Addis Ababa | Lideta sub city | Ethiopia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29696707 | Derived | Bekele A, Gebreselassie N, Ashenafi S, Kassa E, Aseffa G, Amogne W, Getachew M, Aseffa A, Worku A, Raqib R, Agerberth B, Hammar U, Bergman P, Aderaye G, Andersson J, Brighenti S. Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia. J Intern Med. 2018 Sep;284(3):292-306. doi: 10.1111/joim.12767. Epub 2018 May 23. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014397 | Tuberculosis, Pulmonary |
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D014807 | Vitamin D |
| D002762 | Cholecalciferol |
| C075773 | 4-phenylbutyric acid |
| ID | Term |
|---|---|
| D012632 | Secosteroids |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo tablets | Drug |
|
Peripheral CD4/CD8 T cell counts. Antibodies in lymphocytes secertions (ALS) (S Ashenafi, Thorax, 2012). Quantiferon-in-tube TB-gold (QFT). Plasma levels of vitamin D, LL-37 and also cytokine/chemokine profiles. Functional studies of immune cells (PBMCs). |
| 0, 4, 8, 16, 24 weeks |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D012141 | Respiratory Tract Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002782 |
| Cholestenes |
| D002776 | Cholestanes |
| D013261 | Sterols |
| D008563 | Membrane Lipids |
| D008055 | Lipids |